SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Preclinical safety of topically administered nanostructure lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies

    Vairo C (1), Collantes M (2), Quincoces G (2), Villullas S (3), Peñuelas I  (4), Pastor M (3), Gil AG (5), Gainza E (3), Hernandez RM (6), Igartua M (6), Gainza G (7).

    (1) BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510 Miñano, Araba, Spain; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
    (2) Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510 Miñano, Araba, Spain.
    (4) Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain; Small Animal Imaging Research Unit, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain; Toxicology Unit, Drug Development Unit University of Navarra (DDUNAV), 31008 Pamplona, Spain.
    (6) NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
    (7) BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510 Miñano, Araba, Spain

    International Journal of Pharmaceutics 28 JUNE 2019

  • Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide

    Richardson PG (1), Oriol A (2), Beksac M (3), Liberati AM (4), Galli M (5), Schjesvold F (6), Lindsay J (7), Weisel K (8), White D (9), Facon T (10), San Miguel J (11), Sunami K (12), O'Gorman P (13), Sonneveld P (14), Robak P (15), Semochkin S (16), Schey S (17), Yu X (18), Doerr T (18), Bensmaine A (19), Biyukov T (19), Peluso T (19), Zaki M (18), Anderson K (20), Dimopoulos M (21); OPTIMISMM trial investigators. (1) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (2) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
    (3) Ankara University, Ankara, Turkey.
    (4) Università degli studi di Perugia, Perugia, Italy.
    (5) Azienda Ospedaliera Papa Giovanni XXIII, Unità Operativa di Ematologia, Bergamo, Italy.
    (6) Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; K G Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
    (7) East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
    (8) Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    (9) Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
    (10) University of Lille, Centre Hospitalier Universitaire Lille, Service des Maladies du Sang, Lille, France.
    (11) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (12) National Hospital Organization Okayama Medical Center, Okayama, Japan.
    (13) Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Trials Ireland, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
    (14) Erasmus MC Cancer Institute, Rotterdam, Netherlands.
    (15) Medical University of Lodz, Lodz, Poland.
    (16) Pirogov Russian National Research Medical University, Moscow, Russia
    (17) Department of Hematology, King's College London, London, UK.
    (18) Celgene Corporation, Summit, NJ, USA.
    (19) Celgene International, Boudry, Switzerland.
    (20) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (21) National and Kapodistrian University of Athens, Athens, Greece.

    https://www.ncbi.nlm.nih.gov/pubmed/31097405 13 MAY 2019

  • Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

    Perez-Ruiz E (1,2,3,4,5), Minute L (1,2), Otano I (1,2), Alvarez M (1,2), Ochoa MC (1,2,6), Belsue V (1,2), de Andrea C (2,7), Rodriguez-Ruiz ME (1,3), Perez-Gracia JL (2,3,6), Marquez-Rodas I (6,8), Llacer C (9), Alvarez M (5,10,11), de Luque V (5,10), Molina C (1,2), Teijeira A (1,2,6), Berraondo P (12,13,14), Melero I (15,16,17,18,19).

    (1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Oncology, Hospital Costa del Sol, Marbella, Spain.
    (5) Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Málaga, Spain.
    (6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (7) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (8) Department of Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
    (9) Department of Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
    (10) Laboratorio de Biología Molecular del Cáncer, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.
    (11) Department of Pathology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain.
    (12) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (13) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (14) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (15) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (16) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (17) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (18) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (19) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

    Nature 01 MAY 2019

  • Proximal row carpectomy in patients older than 50 years: 3 to 16 years of follow-up

    Montiel V (1), Payo-Ollero J (2), Amillo S (2).

    (1) Departamento Cirugía Ortopédica y Traumatología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
    (2) Departamento Cirugía Ortopédica y Traumatología, Clínica Universidad de Navarra, Pamplona, Navarra, España.

    Revista Española de Cirugía Ortopédica y Traumatología 26 APRIL 2019

  • Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine

    Grigorian Shamagian L (1,2), Madonna R (3,4), Taylor D (5), Climent AM (1,2), Prosper F (6), Bras-Rosario L (7), Bayes-Genis A (2,8), Ferdinandy P (9,10), Fernández-Avilés F (1,2), Izpisua Belmonte JC (11), Fuster V (2,12,13), Bolli R (14).

    (1) From the Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain (L.G.S., A.M.C., F.F.-A.).
    (2) CIBERCV, ISCIII, Madrid, Spain (L.G.S., A.M.C., A.B.-G., F.F.-A., V.F.).
    (3) Center of Aging Sciences and Translational Medicine (CESI-MeT), Institute of Cardiology, G. d'Annunzio University, Chieti, Italy (R.M.).
    (4) Department of Internal Medicine, the University of Texas Health Science Center at Houston (R.M., ).
    (5) Texas Heart Institute, Houston (D.T.).
    (6) Clinica Universidad de Navarra, Pamplona, Spain (F.P.).
    (7) Cardiology Department, Santa Maria University Hospital (CHLN), Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Portugal (L.B.-R.).
    (8) Hospital Germans Trias i Pujol, Badalona, Spain (A.B.-G.)
    (9) Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary (P.F.).
    (10) Pharmahungary Group, Szeged, Hungary (P.F.).
    (11) Salk Institute for Biological Studies, La Jolla (J.C.I.B.).
    (12) The Mount Sinai Hospital, New York, NY (V.F.).
    (13) Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (V.F.).
    (14) University of Louisville (R.B.).

    Circulation Research 15 MARCH 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra